Search results for "Slow progression"

showing 4 items of 4 documents

CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges.

2020

During the past decades, several therapeutic approaches have been developed and made rapidly available for many patients afflicted with lysosomal storage disorders (LSDs), inborn organelle disorders with broad clinical manifestations secondary to the progressive accumulation of undegraded macromolecules within lysosomes. These conditions are individually rare, but, collectively, their incidence ranges from 1 in 2,315 to 7,700 live-births. Most LSDs are manifested by neurological symptoms or signs, including developmental delay, seizures, acroparesthesia, motor weakness, and extrapyramidal signs. The chronic and later-onset clinical forms are at one end of the continuum spectrum and are char…

0301 basic medicineliposomesWeaknessLysosomal storage disordersReviewexosomesBioinformaticsBiochemistry Genetics and Molecular Biology (miscellaneous)BiochemistryExtracellular vesiclesUnmet needs03 medical and health sciences0302 clinical medicinelysosomesSlow progressionmedicineMolecular Bioscienceslcsh:QH301-705.5Molecular BiologytherapyExtrapyramidal signsbusiness.industryEnzyme replacement therapygene therapysmall molecules030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesismedicine.symptombusinessextracellular vesiclesNeurological problemsenzyme replacement therapyFrontiers in molecular biosciences
researchProduct

Relevance of 3d culture systems to study osteosarcoma environment

2018

Abstract Osteosarcoma (OS) is the most common primary malignant tumor of bone, which preferentially develops lung metastasis. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for patients with metastatic or recurrent OS remains dramatically poor. Novel therapies are therefore required to slow progression and eradicate the disease. Furthermore, to better understand the cellular and molecular mechanisms responsible for OS onset and progression, the development of novel predictive culture systems resembling the native three-dimensional (3D) tumor microenvironment are mandatory. ‘Tumor engineering’ approaches radically changed t…

0301 basic medicineCancer Research3D cell culture system; Osteosarcoma; Scaffolds; SpheroidsLung metastasisCell Culture TechniquesBone NeoplasmsReviewDiseaselcsh:RC254-282Scaffold03 medical and health sciences3D cell culture0302 clinical medicineSettore BIO/13 - Biologia ApplicataSlow progressionSpheroids CellularTumor MicroenvironmentmedicineAnimalsHumans3D cell culture systemScaffoldsOsteosarcomaTumor microenvironmentTissue Scaffoldsbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good healthClinical Practice030104 developmental biologyOncologyCell culture030220 oncology & carcinogenesisCancer researchOsteosarcomaSpheroidsbusinessJournal of Experimental & Clinical Cancer Research
researchProduct

X-Linked myopathy with excessive autophagy: A new hereditary muscle disease

1988

We report on 3 brothers with a myopathy that also affected their maternal grandfather and great-uncle. Characteristic features are onset in early childhood, very slow progression, normal life expectancy, weakness of proximal limb muscles, especially in the legs, elevation of serum creatine kinase, and no cardiac or intellectual involvement. In biopsy material muscle fibers are almost never necrotic but show excessive autophagic activity and exocytosis of the phagocytosed material. We suggest that this family has an undescribed type of congenital myopathy, for which we propose the name X-linked myopathy with excessive autophagy.

WeaknessPathologymedicine.medical_specialtybusiness.industryAutophagyAnatomymedicine.diseaseCongenital myopathyX-linked myopathy with excessive autophagyMuscle diseaseNeurologySlow progressionMedicineNeurology (clinical)Biopsy materialmedicine.symptombusinessMyopathyAnnals of Neurology
researchProduct

Treatment strategies for lysosomal storage disorders.

2017

Over the past several years the number of treatments available for patients with lysosomal storage disorders has rapidly increased. Haematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction, and chaperone therapies are currently available, and gene therapies and other treatments are rapidly advancing. Despite remarkable advances, the efficacy of most of these therapies is limited, particularly because the treatments are usually initiated when organ damage has already occurred. To circumvent this limitation, screening in newborn infants for lysosomal storage disorders has been introduced in many countries. However, this screening is complicated by the broad cl…

0301 basic medicineGenetic enhancementLysosomal storage disordersBioinformatics03 medical and health sciences0302 clinical medicineDevelopmental NeuroscienceSlow progressionMedicineHumansEnzyme Replacement Therapybusiness.industryHematopoietic Stem Cell TransplantationEnzyme replacement therapyGenetic TherapyOrgan damageTransplantationLysosomal Storage Diseases030104 developmental biologyPediatrics Perinatology and Child HealthImmunologyTreatment strategyNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryMolecular ChaperonesDevelopmental medicine and child neurology
researchProduct